COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area

Autor: Vuagnat, Perrine, Frelaut, Maxime, Ramtohul, Toulsie, Basse, Clémence, Diakite, Sarah, Noret, Aurélien, Bellesoeur, Audrey, Servois, Vincent, Hequet, Delphine, Laas, Enora, Kirova, Youlia M., Cabel, Luc, Pierga, Jean Yves, Alimi, Aurélia, Belotti, Muriel, Bensaoula, Okba, Bertrand, Ophélie, Bilger, Geoffroy, Brain, Étienne G.C., Brisse, Hervé, Buecher, Bruno, Chanas, Laetitia, Chapus, Caroline, Charles-Massar, Isabelle, Chérel, Pascal J.P., Créhange, Gilles, Colas, Christelle, Delhomelle, Hélène, Frederic-Moreau, Thomas, Fourme, Emmanuelle, Fumoleau, Pierre, Gauthier-Villars, Marion, Lantz, Olivier, Lassalle, Sophie, Le Mentec, Marine, Lerebours, Florence, Loirat, Delphine, Minsat, Mathieu, Pauline, Moreau, De Pauw, Antoine, Priour, Maël, Reyal, Fabien, Rouzier, Roman, Saad, Mary, Saule, Claire, Sebbag, Clara, Stoppa-Lyonnet, Dominique, Tardivon, Anne A., Takanen, Silvia, Vanjak, Dominíque, Villy, Marie Charlotte, Vincent-Salomon, Anne, Warcoin, Mathilde, Bozec, Laurence, Paoletti, Xavier, Cottu, Paul Henri, Bidard, François Clément
Přispěvatelé: Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut Curie [Paris], Institut Curie [Saint-Cloud], Cancer et génome: Bioinformatique, biostatistiques et épidémiologie d'un système complexe, MINES ParisTech - École nationale supérieure des mines de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Survival
medicine.medical_treatment
law.invention
0302 clinical medicine
Breast cancer
law
Risk Factors
Cause of Death
030212 general & internal medicine
Lung
Outcome
Mortality rate
Middle Aged
Prognosis
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Intensive care unit
Metastatic breast cancer
3. Good health
Hospitalization
Treatment Outcome
030220 oncology & carcinogenesis
RNA
Viral
Female
France
Coronavirus Infections
Research Article
medicine.medical_specialty
Pneumonia
Viral
[SDV.CAN]Life Sciences [q-bio]/Cancer
Breast Neoplasms
lcsh:RC254-282
03 medical and health sciences
Betacoronavirus
Radiologic sign
Internal medicine
medicine
Humans
Medical history
Pandemics
Aged
COVID-19
SARS-CoV-2
business.industry
Cancer
medicine.disease
Radiation therapy
business
Tomography
X-Ray Computed
Zdroj: Breast Cancer Research, Vol 22, Iss 1, Pp 1-10 (2020)
Breast Cancer Research : BCR
Breast Cancer Research
Breast Cancer Research, BioMed Central, 2020, 22 (1), ⟨10.1186/s13058-020-01293-8⟩
Breast cancer research, 22(1):55
ISSN: 1465-5411
DOI: 10.1101/2020.04.30.20085928
Popis: Background Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics and outcome of patients diagnosed with COVID-19 during breast cancer treatment at Institut Curie hospitals (ICH, Paris area, France). Methods An IRB-approved prospective registry was set up at ICH on March 13, 2020, for all breast cancer patients with COVID-19 symptoms or radiologic signs. Registered data included patient history, tumor characteristics and treatments, COVID-19 symptoms, radiological features, and outcome. Data extraction was done on April 25, 2020. COVID-19 patients were defined as those with either a positive RNA test or typical, newly appeared lung CT scan abnormalities. Results Among 15,600 patients actively treated for early or metastatic breast cancer during the last 4 months at ICH, 76 patients with suspected COVID-19 infection were included in the registry and followed. Fifty-nine of these patients were diagnosed with COVID-19 based on viral RNA testing (N = 41) or typical radiologic signs: 37/59 (63%) COVID-19 patients were treated for metastatic breast cancer, and 13/59 (22%) of them were taking corticosteroids daily. Common clinical features mostly consisted of fever and/or cough, while ground-glass opacities were the most common radiologic sign at diagnosis. We found no association between prior radiation therapy fields or extent of radiation therapy sequelae and extent of COVID-19 lung lesions. Twenty-eight of these 59 patients (47%) were hospitalized, and 6 (10%) were transferred to an intensive care unit. At the time of analysis, 45/59 (76%) patients were recovering or had been cured, 10/59 (17%) were still followed, and 4/59 (7%) had died from COVID-19. All 4 patients who died had significant non-cancer comorbidities. In univariate analysis, hypertension and age (> 70) were the two factors associated with a higher risk of intensive care unit admission and/or death. Conclusions This prospective registry analysis suggests that the COVID-19 mortality rate in breast cancer patients depends more on comorbidities than prior radiation therapy or current anti-cancer treatment. Special attention must be paid to comorbidities when estimating the risk of severe COVID-19 in breast cancer patients.
Databáze: OpenAIRE
Externí odkaz: